Industry Leaders Select NeuroHealing’s NH001 Among Top 10 Most Promising Neuroscience Projects Available for Partnering

Newton, Massachusetts – August 11, 2008 – NeuroHealing Pharmaceuticals, a private clinical stage company developing products for individuals with chronic brain injuries and neurodegenerative diseases, today announced that NH001 has been chosen by Windhover Information and independent expert Harry Tracy, as one of the top 10 most interesting neuroscience projects in development available for strategic…

Life Science Angels Makes Additional Investment in NeuroHealing Pharmaceuticals

Newton, Massachusetts – July 22, 2008 Life Science Angels (LSA), a Bay Area healthcare angel investment group focused on biotechnology and medical device companies, has made a further investment in NeuroHealing Pharmaceuticals. With this third round since March 2006, LSA has invested over $650,000 in NeuroHealing. NeuroHealing Pharmaceuticals is a specialty clinical stage neuroscience company…

NeuroHealing Pharmaceuticals Receives Grant from the FDA Office of Orphan Drugs for Clinical Development of NH001 to Treat Patients in a Vegetative and Minimally Conscious State

Receipt of Peer-Reviewed Competitive Grant Acknowledges Promise of NH001 As a Treatment for Patients in a Comatose State following a Traumatic Brain Injury Newton, Massachusetts – July 16, 2008 NeuroHealing Pharmaceuticals, a company developing products for individuals with chronic brain injuries, today announced that the Food and Drug Administration (FDA) has awarded the company a…

NeuroHealing Pharmaceuticals Initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease Patients

Newton, Massachusetts – February 19, 2008 NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the initiation of a Phase II clinical trial of NH004 for the treatment of sialorrhea (uncontrolled drooling) in Parkinson’s disease (PD) patients. The first patients have been enrolled, and dosing was initiated…

NeuroHealing Pharmaceuticals Appoints Burt Adelman, M.D., to Board of Directors

Newton, Massachusetts – January 3, 2008 NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced the appointment of Burt A. Adelman, M.D., to the company’s Board of Directors. Burt Adelman M.D. was most recently Executive Vice President, Portfolio Strategy at Biogen Idec, having retired from this position…

The Michael J. Fox Foundation Awards Funding To NeuroHealing Pharmaceuticals Researchers for a Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease Patients

Newton, Massachusetts – December 13, 2007 NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, today announced that the Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded the company a grant to advance the clinical development of NH004, a novel treatment for sialorrhea (uncontrolled drooling). This grant…

NeuroHealing Pharmaceuticals Presents Clinical Data for NH001 in Coma Recovery at The American Society for Experimental NeuroTherapeutics (ASENT) Annual Meeting

Newton, Mass., March 12, 2007 NeuroHealing Pharmaceuticals Inc., a a clinical stage private company developing products for individuals with chronic brain injuries, today announced that it had presented new clinical data for its coma recovery compound, NH001, at the American Society for Experimental NeuroTherapeutics (ASENT) 9th annual meeting, held in Washington, DC from March 7-10,…

NeuroHealing Pharmaceuticals CEO, Neal Farber, to Speak at The Dow Jones Venturewire Health Care Innovations 2006 Conference, The Biotech & Life Sciences Global Venture Congress 2006, and The Life Sciences Venture Summit 2006

Newton, Mass., September 12, 2006. NeuroHealing Pharmaceuticals Inc., a private company developing innovative therapeutic products for neuro- rehabilitation, today announced that its CEO Neal M. Farber, Ph.D., has accepted invitations to speak at three upcoming investor conferences. Dr. Farber will speak at the Dow Jones VentureWire Health Care Innovations conference scheduled for September 12-13 at…